Annual report
4886.TEDINET S100R645
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 72
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥60.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥5.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥87.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥32.6bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥54.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥44.5bn | at 2021-03-31d | Cons. | Net assets |
| Cash and deposits | ¥14.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥150.08 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,928.14 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 747 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 777 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥1.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥658m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥603m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥603m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥591m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥682m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥41.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥41.3bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥630m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥606m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥40.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.7bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥820m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥20.95 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,447.55 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.5% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.5% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 30,563,199 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Employees | 79 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 74 | at 2022-03-31 | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 14 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥298m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥220m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥77m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥6m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥481m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥77m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥77m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥43.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Animal Health Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4m |
| Animal Health Businessreportable segment | employees | at 2023-03-31 | 36 pure |
| Animal Health Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | segment assets | at 2023-03-31 | ¥3.0bn |
| Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥409m |
| Pharmaceutical Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | employees | at 2023-03-31 | 610 pure |
| Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥53.6bn |
| Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥53.6bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2023-03-31 | ¥40.1bn |
| Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥60.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥60.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥77m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥43.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥6.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥259m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥185m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥90m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥136m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥37.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥653m |
| Animal Health Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥4m |
| Animal Health Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥5.6bn |
| Animal Health Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥5.6bn |
| Animal Health Businessreportable segment | segment assets | at 2022-03-31 | ¥3.0bn |
| Animal Health Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥376m |
| Pharmaceutical Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2022-03-31 | ¥42.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥56.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥56.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥46.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,440
| Item | Context | Value | Unit |
|---|---|---|---|
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and associates and reasons for not being accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Other specific information if deemed necessary about application of equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in presentation consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes additional information consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding shares and bonds etc of unconsolidated subsidiaries and associates (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding guarantee obligations (text) | CurrentYearInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding write downs of inventories (text) | CurrentYearDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding gain on sales of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes securities consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes retirement benefits consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes tax effect accounting consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes business combinations consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes asset retirement obligations consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes real estate for lease etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes revenue recognition consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Description of reportable segments (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of changes in reportable segments (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 22 of 22 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |